Article(id=1236346469976953763, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236346464578891843, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1673020800000, acceptedDateStr=2023-01-07, onlineDate=1772697568648, onlineDateStr=2026-03-05, pubDate=1684080000000, pubDateStr=2023-05-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1772697568648, onlineIssueDateStr=2026-03-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1772697568648, creator=13701087609, updateTime=1772697568648, updator=13701087609, issue=Issue{id=1236346464578891843, tenantId=1146029695717560320, journalId=1235980733773295621, year='2023', volume='32', issue='9', pageStart='865', pageEnd='968', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1772697567361, creator=13701087609, updateTime=1772697682369, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1236346947028701631, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236346464578891843, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1236346947028701632, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236346464578891843, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=916, endPage=920, ext={EN=ArticleExt(id=1236346470207640502, articleId=1236346469976953763, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Inetetamab combining pyrotinib as second-line treatment of HER2-positive patients: A case report, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=
Objective:

To explore the safety and efficacy of Inetetamab combined with Pyrotinib in the treatment of HER2-positive breast cancer.

Methods:

A case of patient was reported with right breast invasive ductal carcinoma with multiple systemic metastases. The patients were found progressing after 3 cycles of docetaxel+Capecitabine+Trastuzumab regimen as the first line therapy for Trastuzumab primary resistance. Second-line therapy combined inetetamab with pyrotinib (inetetamab 8 mg·kg-1 for the first time, followed by 6 mg·kg-1, q3w+pyrotinib 400 mg·d-1, qd+vinorelbine 35 mg day 1, day 8 q3w) for 18 cycles.

Results:

The patients achieved partial response (PR) at the first evaluation. During the 18 cycles of treatment, the efficacy was evaluated as continuous PR. The current progress free survival (PFS) was more than 16 months. No grade III or above adverse reactions occurred during the treatment, and the patients were well tolerated.

Conclusion:

The combination of inetetamab with pyrotinib is effective and safe in the treatment of metastatic HER2-positive breast cancer.

, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Yang LI, Wei PENG, Jin-cai ZHONG), CN=ArticleExt(id=1236346470467687372, articleId=1236346469976953763, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=伊尼妥单抗联合吡咯替尼二线治疗HER2阳性患者1例, columnId=1236331162205999476, journalTitle=中国新药杂志, columnName=临床研究, runingTitle=null, highlight=null, articleAbstract=
目的:

探索伊尼妥单抗联合吡咯替尼治疗HER2阳性乳腺癌患者的安全性及疗效。

方法:

报道1例右乳腺浸润性导管癌并全身多处转移患者,一线使用多西他赛+卡培他滨+曲妥珠单抗方案3周期后进展,为曲妥珠单抗原发耐药患者,二线使用含伊尼妥单抗联合吡咯替尼方案(伊尼妥单抗首次8 mg·kg-1,之后6 mg·kg-1,3周1次+吡咯替尼400 mg·d-1qd+长春瑞滨35 mg,d 1,d 8,3周1次 ),应用此方案共18周期。

结果:

患者第1次评价疗效即达到部分缓解,在18周期治疗期间,评价疗效为持续部分缓解状态,目前无进展生存期已大于16个月。治疗过程中未出现Ⅲ级及以上不良反应,患者耐受良好。

结论:

伊尼妥单抗联合吡咯替尼的治疗模式对转移性HER2阳性乳腺癌有一定的临床疗效,安全性良好。

, correspAuthors=null, authorNote=null, correspAuthorsNote=
钟进才,男,主任医师,研究生导师,主要从事乳腺癌等恶性肿瘤综合治疗及癌痛、营养等方向的研究。E-mail:
, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=iDHDg5ePC+qp9x+PtHB53Q==, magXml=J2LuzsXpmBqm/i+roVuU5A==, pdfUrl=null, pdf=8i7ewYR7UqE9tvDTL735fg==, pdfFileSize=5481650, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=4IWJYAKruDnlWB/HeI3IgA==, mapNumber=null, authorCompany=null, fund=null, authors=

李扬,女,主任医师,主要从事乳腺癌等恶性肿瘤的综合治疗。E-mail:

, authorsList=李扬, 彭巍, 钟进才)}, authors=[Author(id=1236346470832591848, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=young88818@168.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1236346470987781107, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346470832591848, language=EN, stringName=Yang LI, firstName=Yang, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1236346471105221625, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346470832591848, language=CN, stringName=李扬, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广西医科大学第一附属医院肿瘤内科,南宁 530021, bio={"content":"

李扬,女,主任医师,主要从事乳腺癌等恶性肿瘤的综合治疗。E-mail:

"}, bioImg=null, bioContent=

李扬,女,主任医师,主要从事乳腺癌等恶性肿瘤的综合治疗。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1236346470710957021, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, xref=null, ext=[AuthorCompanyExt(id=1236346470715151327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China), AuthorCompanyExt(id=1236346470731928545, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学第一附属医院肿瘤内科,南宁 530021)])]), Author(id=1236346471197496319, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1236346471289769985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346471197496319, language=EN, stringName=Wei PENG, firstName=Wei, middleName=null, lastName=PENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1236346471407210503, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346471197496319, language=CN, stringName=彭巍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广西医科大学第一附属医院肿瘤内科,南宁 530021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1236346470710957021, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, xref=null, ext=[AuthorCompanyExt(id=1236346470715151327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China), AuthorCompanyExt(id=1236346470731928545, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学第一附属医院肿瘤内科,南宁 530021)])]), Author(id=1236346471499485194, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1093301007@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1236346471595954193, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346471499485194, language=EN, stringName=Jin-cai ZHONG, firstName=Jin-cai, middleName=null, lastName=ZHONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1236346471671451672, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, authorId=1236346471499485194, language=CN, stringName=钟进才, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广西医科大学第一附属医院肿瘤内科,南宁 530021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1236346470710957021, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, xref=null, ext=[AuthorCompanyExt(id=1236346470715151327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China), AuthorCompanyExt(id=1236346470731928545, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学第一附属医院肿瘤内科,南宁 530021)])])], keywords=[Keyword(id=1236346471772114971, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=EN, orderNo=1, keyword=inetetamab), Keyword(id=1236346471830835235, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=EN, orderNo=2, keyword=pyrotinib), Keyword(id=1236346471897944104, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=EN, orderNo=3, keyword=breast cancer), Keyword(id=1236346471986024494, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=CN, orderNo=1, keyword=伊尼妥单抗), Keyword(id=1236346472057327664, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=CN, orderNo=2, keyword=吡咯替尼), Keyword(id=1236346472145408054, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, language=CN, orderNo=3, keyword=乳腺癌)], refs=null, funds=[Fund(id=1236346472237682748, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, awardId=x202210598326, language=CN, fundingSource=广西医科大学2022年大学生创新创业训练计划项目(x202210598326), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1236346470710957021, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, xref=null, ext=[AuthorCompanyExt(id=1236346470715151327, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China), AuthorCompanyExt(id=1236346470731928545, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236346469976953763, companyId=1236346470710957021, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学第一附属医院肿瘤内科,南宁 530021)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1772610649152, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=C, firstLetterEn=C, subjectCode=Life Sciences, subjectName=null, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1235981903275290962, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1772610649174, updatedTime=1772610649174, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1235981903338205523, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1772610649189, updatedTime=1772610649189, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=C, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2023/V32/I9/916, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2023/V32/I9/916, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2023/V32/I9/916, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2023/V32/I9/916, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)
收藏切换
伊尼妥单抗联合吡咯替尼二线治疗HER2阳性患者1例
收藏切换
PDF下载
李扬 , 彭巍 , 钟进才
中国新药杂志 | 临床研究 2023,32(9): 916-920
收起
收藏切换
中国新药杂志 | 临床研究 2023, 32(9): 916-920
伊尼妥单抗联合吡咯替尼二线治疗HER2阳性患者1例
全屏
李扬 , 彭巍, 钟进才
作者信息
  • 广西医科大学第一附属医院肿瘤内科,南宁 530021
  • 李扬,女,主任医师,主要从事乳腺癌等恶性肿瘤的综合治疗。E-mail:

通讯作者:

钟进才,男,主任医师,研究生导师,主要从事乳腺癌等恶性肿瘤综合治疗及癌痛、营养等方向的研究。E-mail:
Inetetamab combining pyrotinib as second-line treatment of HER2-positive patients: A case report
Yang LI , Wei PENG, Jin-cai ZHONG
Affiliations
  • Department of Medical Oncology, The First Affifiliated Hospital of Guangxi Medical University, Nanning 530021, China
出版时间: 2023-05-15
文章导航
收藏切换
目的:

探索伊尼妥单抗联合吡咯替尼治疗HER2阳性乳腺癌患者的安全性及疗效。

方法:

报道1例右乳腺浸润性导管癌并全身多处转移患者,一线使用多西他赛+卡培他滨+曲妥珠单抗方案3周期后进展,为曲妥珠单抗原发耐药患者,二线使用含伊尼妥单抗联合吡咯替尼方案(伊尼妥单抗首次8 mg·kg-1,之后6 mg·kg-1,3周1次+吡咯替尼400 mg·d-1qd+长春瑞滨35 mg,d 1,d 8,3周1次 ),应用此方案共18周期。

结果:

患者第1次评价疗效即达到部分缓解,在18周期治疗期间,评价疗效为持续部分缓解状态,目前无进展生存期已大于16个月。治疗过程中未出现Ⅲ级及以上不良反应,患者耐受良好。

结论:

伊尼妥单抗联合吡咯替尼的治疗模式对转移性HER2阳性乳腺癌有一定的临床疗效,安全性良好。

伊尼妥单抗  /  吡咯替尼  /  乳腺癌
Objective:

To explore the safety and efficacy of Inetetamab combined with Pyrotinib in the treatment of HER2-positive breast cancer.

Methods:

A case of patient was reported with right breast invasive ductal carcinoma with multiple systemic metastases. The patients were found progressing after 3 cycles of docetaxel+Capecitabine+Trastuzumab regimen as the first line therapy for Trastuzumab primary resistance. Second-line therapy combined inetetamab with pyrotinib (inetetamab 8 mg·kg-1 for the first time, followed by 6 mg·kg-1, q3w+pyrotinib 400 mg·d-1, qd+vinorelbine 35 mg day 1, day 8 q3w) for 18 cycles.

Results:

The patients achieved partial response (PR) at the first evaluation. During the 18 cycles of treatment, the efficacy was evaluated as continuous PR. The current progress free survival (PFS) was more than 16 months. No grade III or above adverse reactions occurred during the treatment, and the patients were well tolerated.

Conclusion:

The combination of inetetamab with pyrotinib is effective and safe in the treatment of metastatic HER2-positive breast cancer.

inetetamab  /  pyrotinib  /  breast cancer
李扬, 彭巍, 钟进才. 伊尼妥单抗联合吡咯替尼二线治疗HER2阳性患者1例. 中国新药杂志, 2023 , 32 (9) : 916 -920 .
Yang LI, Wei PENG, Jin-cai ZHONG. Inetetamab combining pyrotinib as second-line treatment of HER2-positive patients: A case report[J]. Chinese Journal of New Drugs, 2023 , 32 (9) : 916 -920 .
  • 广西医科大学2022年大学生创新创业训练计划项目(x202210598326)
2023年第32卷第9期
PDF下载
42
16
引用本文
BibTeX
文章信息
  • 首发时间:2026-03-05
  • 出版时间:2023-05-15
补充材料
相关文章
文章信息
作者
出版历史
  • 录用日期:2023-01-07
基金
广西医科大学2022年大学生创新创业训练计划项目(x202210598326)
作者信息
    广西医科大学第一附属医院肿瘤内科,南宁 530021

通讯作者:

钟进才,男,主任医师,研究生导师,主要从事乳腺癌等恶性肿瘤综合治疗及癌痛、营养等方向的研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1236346469976953763
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏